| Theme |
Preventive Medicine of Gastrointestinal Cancer |
| Title |
Chemoprevention of Gastric Cancer with Helicobacter pylori Eradication Therapy |
| Author |
Jun Miwa |
Department of Gastroenterology, Toshiba General Hospital |
| Author |
Mitsuru Kaise |
Department of Endoscopy, The Jikei University School of Medicine |
| Author |
Jun Tashiro |
Department of Gastroenterology, Toshiba General Hospital |
| Author |
Takashige Tomita |
Department of Gastroenterology, Toshiba General Hospital |
| Author |
Yasuo Matsubara |
Department of Gastroenterology, Toshiba General Hospital |
| Author |
Hisao Tajiri |
Department of Gastroenterology & Hapatology, The Jikei University School of Medicine |
| [ Summary ] |
Helicobacter pylori (H. pylori) is a crucial carcinogen in gastric tumorgenesis, and eradication of H. pylori may prevent the incidence of gastric cancer. However, it is impractical to eradicate H. pylori-infection in all individuals, because an estimated 60 million Japanese would test positive for H. pylori.
To produce better preventive effects, it is necessary to select high risk gastric cancer groups, especially in younger populations, who have no precancerous lesions such as gastric atrophy or intestinal metaplasia. |